Myriad Genetics, Inc. Forecast, price target & analysts
Myriad Genetics, Inc. Target price 2025 - Analyst rating & recommendation
Myriad Genetics, Inc. Classifications & Recommendation:
Myriad Genetics, Inc. Price Target
| Target Price | $6.63 |
| Price | $6.68 |
| Deviation |
0.75%
register free of charge
|
| Number of Estimates | 14 |
|
14 Analysts have issued a price target Myriad Genetics, Inc. 2026 .
The average Myriad Genetics, Inc. target price is $6.63.
This is
0.75%
register free of charge
$18.90
182.93%
register free of charge
$3.54
47.08%
register free of charge
|
|
| A rating was issued by 19 analysts: 3 Analysts recommend Myriad Genetics, Inc. to buy, 10 to hold and 6 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Myriad Genetics, Inc. stock has an average upside potential 2026 of
0.75%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 837.60 | 838.09 |
| 11.21% | 0.06% | |
| EBITDA Margin | -3.20% | 3.48% |
| 67.87% | 208.76% | |
| Net Margin | -15.20% | 0.05% |
| 56.52% | 100.33% |
16 Analysts have issued a sales forecast Myriad Genetics, Inc. 2025 . The average Myriad Genetics, Inc. sales estimate is
This results in the following potential growth metrics:
14 Analysts have issued an Myriad Genetics, Inc. EBITDA forecast 2025. The average Myriad Genetics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
16 Myriad Genetics, Inc. Analysts have issued a net profit forecast 2025. The average Myriad Genetics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.41 | 0.00 |
| 55.66% | 100.00% | |
| P/E | 1,417.54 | |
| EV/Sales | 0.73 |
Current Myriad Genetics, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Wells Fargo |
Locked
➜
Locked
|
Locked | Nov 05 2025 |
| TD Cowen |
Locked
➜
Locked
|
Locked | Nov 04 2025 |
| UBS |
Locked
➜
Locked
|
Locked | Nov 04 2025 |
| Scotiabank |
Locked
➜
Locked
|
Locked | May 21 2025 |
| Piper Sandler |
Locked
➜
Locked
|
Locked | May 15 2025 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | May 08 2025 |
| UBS |
Locked
➜
Locked
|
Locked | May 07 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Nov 05 2025 |
|
Locked
TD Cowen:
Locked
➜
Locked
|
Nov 04 2025 |
|
Locked
UBS:
Locked
➜
Locked
|
Nov 04 2025 |
|
Locked
Scotiabank:
Locked
➜
Locked
|
May 21 2025 |
|
Locked
Piper Sandler:
Locked
➜
Locked
|
May 15 2025 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
May 08 2025 |
|
Locked
UBS:
Locked
➜
Locked
|
May 07 2025 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
